Innate Pharma S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IPH.PA | HURA | IMRX | CHRS | MGNX | ARTV | |
|---|---|---|---|---|---|---|
| Market cap | 144.54M | 109.61M | 243.51M | 131.36M | 147.15M | 206.32M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 1.4 | -2.8 | -3.0 | -1.3 | -1.6 | -2.1 |
| Price/book | -3.0 | 6.0 | 1.4 | 2.2 | 3.4 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −23.85% | −33.80% | −43.20% | −42.95% | +61.81% | +22.09% |
| Today | +3.18% | +3.93% | +2.17% | +5.54% | −0.86% | +0.48% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IPH.PA news ›Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the…
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
BioSpace Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference MARSEILLE, France--(BUSINESS WIRE)--#Biotech--Regulatory News: Innate Pha
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial…
Innate Pharma schedules Q3 update for November 5, 2026
The Q3 update call for Innate Pharma (IPHA) starts November 5 at 8 a.m. ET. Stock Titan - [6-K] Innate Pharma SA Current Report (Foreign Issuer) Innate Pharma schedules Q3 update for November 5, 2026 The webcast replay will be available on…
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Now Rated “Moderate Buy” by Wall Street Analysts
Posted by Michael Walen on Oct 7th, 2026 Read Our Latest Analysis on Innate Pharma Innate Pharma’s pipeline has included lacutamab, an antibody targeting KIR3DL2 for the treatment of certain T-cell lymphomas, including cutaneous T-cell…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net3
- biospace.com2
- financialcontent.com1
- rutlandherald.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.